Bone cancer is particularly difficult to treat due to
its poor response to conventional chemotherapy and other, non-surgical,
methods. Researchers at Chongqing Medical University used PLGA (cat# AP041)
from PolySciTech Division of Akina, Inc. (www.polyscitech.com)
to create nanobubbles for transfer of genes into target cells using ultrasound.
This research holds promise to provide for non-invasive therapies for bone
cancer. Read more: Ren, Honglei, Shanlin Xiang, Aiguo Liu, Qian Wang, Nian
Zhou, and Zhenming Hu. "A noval noninvasive targeted therapy for
osteosarcoma: the combination of LIFU and ultrasound-magnetic-mediated
SPIO/TP53/PLGA nanobubble." Frontiers in Bioengineering and Biotechnology
12 (2024): 1418903. https://www.frontiersin.org/articles/10.3389/fbioe.2024.1418903/full
“Purpose: Osteosarcoma (OS) is the most common type of
primary malignant bone tumor. Transducing a functional TP53 gene can
effectively inhibit OS cell activity. Poly lactic acid-glycolic acid (PLGA)
nanobubbles (NBs) mediated by focused ultrasound (US) can introduce exogenous
genes into target cells in animal models, but this technique relies on the
passive free diffusion of agents across the body. The inclusion of
superparamagnetic iron oxide (SPIO) in microbubbles allows for magnetic-based
tissue localization. A low-intensity-focused ultrasound (LIFU) instrument was
developed at our institute, and different intensities of LIFU can either
disrupt the NBs (RLI-LIFU) or exert cytocidal effects on the target tissues
(RHI-LIFU). Based on these data, we performed US-magnetic-mediated TP53-NB
destruction and investigated its ability to inhibit OS growth when combined
with LIFU both in vitro and in vivo. Methods: Several SPIO/TP53/PLGA (STP) NB
variants were prepared and characterized. For the in vitro experiments, HOS and
MG63 cells were randomly assigned into five treatment groups. Cell
proliferation and the expression of TP53 were detected by CCK8, qRT-PCR and
Western blotting, respectively. In vivo, tumor-bearing nude mice were randomly
assigned into seven treatment groups. The iron distribution of Perls’ Prussian
blue-stained tissue sections was determined by optical microscopy. TUNEL-DAPI
was performed to examine apoptosis. TP53 expression was detected by qRT-PCR and
immunohistochemistry. Results: SPIO/TP53/PLGA NBs with a particle size of approximately
200 nm were prepared successfully. For in vitro experiments,
ultrasound-targeted transfection of TP53 overexpression in OS cells and
efficient inhibition of OS proliferation have been demonstrated. Furthermore,
in a tumor-bearing nude mouse model, RLI-LIFU-magnetic-mediated SPIO/TP53/PLGA
NBs increased the transfection efficiency of the TP53 plasmid, resulting in
apoptosis. Adding RHI-LIFU to the treatment regimen significantly increased the
apoptosis of OS cells in vivo. Conclusion: Combining LIFU and
US-magnetic-mediated SPIO/TP53/PLGA NB destruction is potentially a novel
noninvasive and targeted therapy for OS.”
PEG-PLA AP041: https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP041#h
NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/
NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/
No comments:
Post a Comment